Our aim is to clarify the factors for early diagnosis of cardiac sarcoidosis (CS) in patients with complete atrioventricular block (CAVB) and its impact on cardiac function after corticosteroid therapy.
S
arcoidosis is a chronic multisystem disorder with unknown etiology and causes malfunction of various organs through the formation of non-caseating granuloma. 1, 2) Cardiac involvement induces congestive heart failure and ventricular tachycardia and is a crucial factor for the prognosis. 1) Clinically manifested cardiac involvement occurs in 5% of patients with systemic sarcoidosis, and clinically silent cardiac involvement occurs in at least 20% of patients with pulmonary/systemic sarcoidosis. [3] [4] [5] The poor prognosis of cardiac sarcoidosis (CS) may be improved by corticosteroid therapy; 6) however, the limited efficacy is reported in patients with decreased left ventricular ejection fraction (LVEF). 7) In fact, we sometimes encounter a certain type of patient; CS diagnosis was made because of the heart failure with decreased LVEF though the pacemaker was previously implanted for the complete atrioventricular block (CAVB). Taking these together, the early diagnosis and prompt therapeutic intervention immediately after the onset of CAVB might be desirable in CS patients to preserve cardiac function. The purpose of this study was (1) to clarify the clinical characteristics and examination findings for the early diagnosis of CS and (2) to clarify the course of cardiac function according to the time from the CAVB onset to the diagnosis of CS.
Methods
Study population: From January 2005 to December 2014, a total of 15 CS patients with CAVB were retrospectively analyzed in this study ( Figure 1 ). In 10 patients, CAVB served as a trigger for the diagnosis of CS, and these patients underwent corticosteroid therapy immediately after the diagnosis. They were classified into the early diagnosis group (group E). On the other hand, the diagnosis of CS was made over 1 year after the onset of CAVB in five patients. They were classified into the late diagnosis group (group L). The clinical characteristics, ex-Kaida, ET AL adequate. Categorical variables are expressed as number of subjects and proportion, and the analysis was assessed using Fisher test. A difference that was recognized in the 95% confidence interval was defined as statistically significant. A P value < 0.05 was used to indicate statistical significance. All analyses were performed using JMP version 12.0.1 for Windows (SAS, North Carolina, USA).
Results

Characteristics at CAVB onset:
The average days from the CAVB onset to the CS diagnosis was 53.5 ± 35.8 days in group E and 1569 ± 581.8 days in group L (P < 0.0001). There was no significant difference in clinical characteristics and laboratory findings at CAVB onset between group E and group L other than the history of extracardiac sarcoidosis (60 versus 0%, P = 0.0440) ( Table  I ). The findings on imaging examination are shown in Table II. The incidence of abnormal findings on echocardiography was significantly higher in group E than in group L (70 versus 0%, P = 0.0256). LVEF on echocardiography at the time of CAVB onset was significantly lower in group E than in group L (51.7 ± 14.1 versus 66.2 ± 6.1 %, P = 0.0494). Other imaging examinations including chest computed tomography (CT) and 67-gallium scintigraphy (Ga scintigraphy) were more frequently conducted in group E than in group L (90 versus 20%, P = 0.0170, 100% versus 20%, P = 0.0003, respectively). The cardiac magnetic resonance (CMR) imaging was performed in five cases in group E and was not performed in any case in group L at CAVB onset. The details of echocardiography findings and extracardiac sarcoidosis at CAVB onset in individual cases are shown in Table III . Clinical manifestation at CS diagnosis: Among the group E patients, only one patient (10%) suffered congestive heart failure, and another two patients (20%) had severe ventricular arrhythmia during the CAVB onset to CS diagnosis. On the other hand, a total of four patients (80%) had congestive heart failure during the period (Table IV). Detailed echocardiography findings and extracardiac sarcoidosis at CS diagnosis in group L are described in Table V .
EARLY DIAGNOSIS IN CARDIAC SARCOIDOSIS
Course of cardiac function according to the timing of CS diagnosis:
The serial of LVEF and serum brain natriuretic peptide (BNP) levels are shown in Figure 2 and Supplemental Table. Although the LVEF was significantly worse in group E than in group L at the CAVB onset, it was significantly better in group E than in group L (52.5 ± 15.0 versus 33.8 ± 11. 2%, P = 0.0290) at the time of CS diagnosis and after corticosteroid therapy (53.3 ± 10.7 versus 37.0 ± 9.3%, P = 0.0128). The BNP level after corticosteroid therapy was also significantly better in group E than in group L (63.0 ± 46.4 versus 458.8 ± 352.0 pg/mL, P = 0.0027) though it was comparable at CAVB onset (307.8 ± 282.1 versus 263.2 ± 161.8 pg/mL, P = 0.8368). Absolute change of LVEF and BNP levels: The absolute change of LVEF from the CAVB onset to CS diagnosis was significantly smaller in group E than in group L (0.8 ± 2.8 versus -32.4 ± 3.9%, P < 0.0001) ( Figure 3A ). The improvement of LVEF after corticosteroid therapy was unclear in both groups without significant difference between the two groups. The increase of BNP level from the CAVB onset to CS diagnosis was significantly smaller in group E than in group L (-11.1 ± 16.0 versus 161.8 ± 35.8 pg/mL, P = 0.0013) ( Figure 3B ). The decrease of BNP level after corticosteroid therapy appeared larger in group E than in group L without statistical significance. Adv indicates advanced atrioventricular block; AVB, atrioventricular block; CAVB, complete atrioventricular block; CHF, congestive heart failure; CMR, cardiovascular magnetic resonance; CS, cardiac sarcoidosis; IVS, interventricular septum; Ga, gallium scintigraphy; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; M (II), second-degree atrioventricular block Mobitz type II; NA, no abnormality; T2, T2 high intensity; PMI, pacemaker implant; and VA, ventricular arrhythmia.
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Discussion
The major findings of the present study are (1) abnormal findings on echocardiography and the history of extracardiac sarcoidosis were the characteristics of CS patients with early diagnosis and (2) cardiac function was well preserved in the early diagnosis group as compared with the late diagnosis group at CS diagnosis and after corticosteroid therapy. Importance of early diagnosis of CS: The CS patients have poorer prognosis than patients without cardiac involvement because of the risk of cardiac sudden death 10) and heart failure. 11) In particular, left ventricular dysfunction is a crucial factor for survival. 12, 13) Although the specific regimen to improve the prognosis of CS patients have not been developed yet, the immunosuppression ther- apy with corticosteroid is reportedly having the potential to improve the prognosis of CS. 6) However, some reports indicate the limited efficacy of corticosteroid in patients with LVEF < 35%. 7) Thus, the early diagnosis of CS before the deterioration of cardiac function might be desirable to preserve cardiac function and subsequent clinical course. 11) In the present study, the patients who were diagnosed with CS within 1 year from the onset of CAVB had the better course of cardiac function assessed by LVEF and BNP level. Although the prognosis had not been evaluated in the present study because of the limited number of study population, the findings may support the importance of the early diagnosis of CS to avoid the deterioration of cardiac function.
Role of echocardiography for early diagnosis of CS:
In recent years, the ability of FDG-PET to detect early stage CS has been focused 14) in addition to the utility for the assessment of disease activity, therapeutic responses and the prognoses of CS. 15) The CMR with late gadolinium enhancement for the screening of CS has also been acknowledged because of the ability to identify small regions of myocardial damage in cases with preserved cardiac function. 12) On the other hand, the conventional assessment using echocardiography still has a significant role for the early diagnosis of CS. Among several abnormal findings on various imaging modalities, the thinning of the ventricular septal base and ventricular aneurysm assessed by echocardiography are reported to have a significant relationship with the prognosis. 16, 17) The current Japanese guideline for CS diagnosis is more focused on the findings of echocardiography by including them as the major criteria 18, 19) as compared with the past guidelines. 9, 20) In addition, echocardiography is a very simple, repeatable, non-invasive, and cost-effective examination. Thus, the repeat and routine echocardiography would strongly support the early diagnosis of CS, particularly in patients with cardiac pacemaker. In fact, in the present study, a total of seven among eight patients in the early diagnosis group revealed abnormal findings on echocardiography in addition to the high frequency of history of extracardiac sarcoidosis. CAVB as the early sign of CS: The onset of CAVB might become an opportunity of diagnosis of CS. Between 19% and 34% of patients presenting with CAVB have previously undiagnosed CS as the underlying etiology. 21, 22) Another report demonstrates that about 11% of patients with pacemaker for CAVB had CS. 23) Thus, the careful screening using multiple imaging modalities for the diagnosis of sarcoidosis should be considered irrespective of the abnormality on echocardiography. 24) In the present study, the screening for CS with imaging modalities was not comprehensively performed in group L at CAVB onset. Unless suspecting CS and doing scrutiny, it may be hard for even experts to make a diagnosis. 25) Although it is unclear how many patients could be diagnosed with CS by the screening before the onset of heart failure, the aggressive diagnostic examination might be better to preserve their cardiac function. Limitation: The present study has several limitations to be declared. First, this study was retrospectively conducted with a small population size at a single center. Cases without LV dysfunction or localized abnormal wall motion may not be diagnosed with CS. We could not exclude the possibility that lung and skin were not appropriately screened or examined at their first CAVB onset, which may cause potential bias. Second, the FDG-PET was not performed to make a diagnosis of CS. Third, the patients with CAVB were exclusively included in this study. Fourth, LVEF was measured under right ventricular pacing at CS diagnosis and after corticosteroid therapy in most cases, which might cause underestimation. 26) Further studies with a larger population including patients without CAVB are required to support the present results. Conclusion: In patients of CS with CAVB without history of extracardiac sarcoidosis, the diagnosis of CS may be delayed. Abnormal findings of echocardiography contributed to early diagnosis of CS. The efficacy of corticosteroid therapy on cardiac function may be enhanced by the early diagnosis.
